Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Provides Update on the FDA Review of EM-100
September 16, 2020
DEER PARK, Ill. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S.
Read More
Eton Pharmaceuticals Announces Appointment of Ingrid Hoos as Senior Vice President of Scientific Affairs
August 31, 2020
DEER PARK, Ill. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Ingrid Hoos as the company’s new Senior Vice President of
Read More
Eton Pharmaceuticals Announces Second Quarter 2020 Financial Results
August 12, 2020
DEER PARK, Ill. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the second quarter ended June 30, 2020 and provided an update on
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.